title: Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas.
abstract: OBJECTIVE
  To demonstrate long-term changes in the prevalence of several types of metabolic derangements in subjects with nonfunctioning adrenal adenomas.
  
  
  METHODS
  273 subjects with adrenal adenomas, including 231 with nonfunctioning adenoma and 42 with subclinical Cushing's syndrome (sCS), were evaluated with respect to anthropometric and laboratory characteristics and prevalence of type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic syndrome (MS), prediabetes and cardiovascular disease (CVD). Median duration was 24 months. Follow-up data of 114 participants with nonfunctioning adrenal adenomas are also presented while those of 117 were missing. Follow-up data regarding changes in anthropometric and laboratory parameters and prevalence rates of metabolic disturbances were obtained from the medical records.
  
  
  RESULTS
  The prevalence rates for both patients with nonfunctioning adenoma and sCS were: dyslipidemia: 161 (59%), hypertension: 147 (54%), MS: 128 (47%), prediabetes: 62 (23%), T2DM: 49 (18%), and CVD: 21 (8%). Hypertension and CVD were prevalent in subjects with sCS compared to participants with nonfunctioning adenoma. In follow-up, body mass index (p = 0.005), systolic blood pressure (p < 0.001), waist circumference (p = 0.005), homeostasis model assessment (p = 0.046), high-sensitivity C-reactive protein (p = 0.023), total cholesterol (p < 0.001) and low-density lipoprotein cholesterol (p < 0.001) and prevalence of hypertension (p < 0.001), dyslipidemia (p < 0.001), prediabetes (p < 0.001) and MS (p < 0.01) significantly increased in subjects with nonfunctioning adenoma.
  
  
  CONCLUSIONS
  The data showed that nonfunctioning adrenal adenomas were associated with the development or deterioration of atherosclerotic risk factors. Therefore, follow-up and management strategies should be developed to decrease atherosclerotic morbidity in those individuals.
authors.affiliation: Division of Endocrinology and Metabolism, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Yener
authors.forename: S
authors.initials: S
authors.lastname: Ertilav
authors.forename: M
authors.initials: M
authors.lastname: Secil
authors.forename: B
authors.initials: B
authors.lastname: Akinci
authors.forename: T
authors.initials: T
authors.lastname: Demir
authors.forename: L
authors.initials: L
authors.lastname: Kebapcilar
authors.forename: S
authors.initials: S
authors.lastname: Yesil
mesh_terms: D000236:Adenoma / Q000453:epidemiology* / Q000378:metabolism; D000310:Adrenal Gland Neoplasms / Q000453:epidemiology* / Q000378:metabolism; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D001837:Body Weights and Measures; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology* / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood; D024821:Metabolic Syndrome / Q000453:epidemiology* / Q000378:metabolism; D008875:Middle Aged; D047748:Pituitary ACTH Hypersecretion / Q000453:epidemiology / Q000378:metabolism; D015995:Prevalence
chemical_list: D008055:Lipids